Information Provided By:
Fly News Breaks for March 19, 2018
HONE, CMI, OSK, DPS, AZN, UL, UN
Mar 19, 2018 | 10:31 EDT
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Unilever (UN, UL) upgraded to Neutral from Sell at Goldman Sachs with the firm's analyst saying valuation reflects growth challenges. 2. AstraZeneca (AZN) upgraded to Buy from Hold at Jefferies with analyst Ian Hilliker saying the company is at a "turning point." 3. Dr Pepper Snapple (DPS) upgraded to Outperform from Sector Perform at RBC Capital saying that some investors have struggled to justify the strategic rationale of the company's Keurig deal, but he sees "several value creation drivers" including leverage in the growing coffee category, improvements for the core Keurig brand, and the prospects for higher cash flow conversion. 4. Oshkosh (OSK) upgraded to Buy from Hold while Cummins (CMI) upgraded to Hold from Sell at Deutsche Bank. 5. HarborOne Bancorp (HONE) upgraded to Buy from Hold at Sandler O'Neill. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
News For UN;UL;AZN;DPS;OSK;CMI;HONE From the Last 2 Days
UL
Mar 19, 2024 | 05:18 EDT
Unilever announced steps to accelerate its "Growth Action Plan" through the separation of Ice Cream and the launch of a productivity program. The board believes Unilever "should be increasingly focused on a portfolio of unmissably superior brands with strong positions in highly attractive categories that have complementary operating models. Ice Cream has a "very different operating model," and as a result the board has decided that the separation of Ice Cream "best serves the future growth of both Ice Cream and Unilever." Following separation, Unilever "will become a simpler, more focused company, operating four Business Groups across Beauty & Wellbeing, Personal Care, Home Care and Nutrition," the company said in a statement. In addition, Unilever said it will continue to optimize its portfolio within the four business groups towards higher growth spaces and through brands with global reach or significant potential to scale.
OSK
Mar 18, 2024 | 09:45 EDT
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's... To see the rest of the story go to thefly.com. See Story Here
AZN
Mar 18, 2024 | 08:17 EDT
Checkpoint Therapeutics (CKPT) announced the appointment of Amit Sharma, M.D., FACP, FASN, FNKF, to its Board as an independent, non-executive director, effective immediately. Dr. Sharma currently serves as Vice President of Clinical Development and Therapeutic Head for Nephrology and Hematology at Alexion, AstraZeneca (AZN) Rare Disease.